

CTI BioPharma Corp. Logo

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

June 13, 2019

SEATTLE, June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City.

Presentation details:

Event: JMP Securities Life Sciences Conference
Date: Thursday, Jun. 20
Time: 2:00 p.m. EDT

About CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:

Argot Partners
Maeve Conneighton/Maghan Meyers
+1-212-600-1902
CTI@argotpartners.com



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-on-thursday-jun-20-300866768.html>

SOURCE CTI BioPharma Corp.